Sponsors Request More Bioequivalence Details in EMA Guideline on Multi-Region Clinical Trials

Drug Industry Daily
A A
Sponsors would like to see clearer recommendations for non-inferiority assessments, demonstrating bioequivalence and targets for statistical analysis, before the European Medicines Agency adopts an international guideline on large clinical trials that span multiple regions.

To View This Article:

Login

Subscribe To Drug Industry Daily